Information  X 
Enter a valid email address

Ergomed plc (ERGO)


Friday 14 May, 2021

Ergomed plc

Notice of AGM and Annual Report

RNS Number : 6079Y
Ergomed plc
14 May 2021




Notice of AGM and Annual Report



Guildford, UK - 14 May 2021 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that its Annual General Meeting ("AGM") will be held at 80 Coleman Street, London, EC2R 6PA at 9:30 a.m. on Thursday, 10 June 2021. In light of the UK government's current COVID-19 measures, it is expected that the AGM will be run as a closed meeting and shareholders will not be able to attend in person.


Ergomed's Annual Report and Accounts for the year ended 31 December 2020, Notice of AGM and Form of Proxy will be available on the Company's website at and are being mailed to its shareholders today.






Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)

James Black (Broker)

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal

[email protected]

Angela Gray


About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: .



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t